Print Page   |   Contact Us   |   Sign In
Community Search
Featured Members

 ADVERTISEMENTS 
This section will be used for adverts.
Pharmaceutical Companies can advertise here.
Adverts will be rated and run on monthly basis.
it will be first come first served basis


BNF:
Available at the PSGH secretariat
  • British National Formulary 
    Book by Royal Pharmaceutical Society of Great Britain and British Medical Association
  • The British National Formulary is a pharmaceutical reference book that contains a wide spectrum of information and advice on prescribing and pharmacology, along with specific facts and details about medicines.
  • PSGH CLOTH and other materials
  • Available at the PSGH Secretariat

  • News & Press: FDA

    Pharm. Mimi Darko appointed new FDA CEO

    Tuesday, February 07, 2017   (2 Comments)
    Posted by: Frank KUMI, Editor
    Share |

    Delese Mimi Darko, a pharmacist, has been appointed by President Akufo-Addo as the new Chief Executive Officer (CEO) of the Food and Drugs Authority (FDA).

    She replaces Hudu Mogtari, also a pharmacist and immediate past CEO of the authority, who was relieved of his appointment recently.

    Ms. Darko, is one of the long-serving officers of the FDA working at the agency since its inception. Not only does this make her appointment unique given that previous CEOs in recent history of the country's regulatory authority had been outsiders, she also occupies the highest executive office of the authority as the first female CEO.

    Brief Profile

    Ms. Darko who graduated from the Kwame Nkrumah University of Science and Technology (KNUST) in 1991 as a pharmacist has served the FDA in various capacities.

    In 1997, she was one of the pioneers of the newly-established Food and Drugs Board (FDB) which later came to be known as the Food and Drugs Authority.

    Ms Darko was in 2005 and 2006 instrumental in the setting up of two technical advisory committees to assist the FDB/FDA in their work.

    With the appointment of Dr Stephen Opuni in 2009 by the Mills/Mahama administration as the new CEO of FDA, the departments that were being headed by Ms Darko at the authority were reportedly downsized, leaving her with just two activities, namely Clinical Trials and Pharmacovigilance.

    She was subsequently appointed onto the WHO/CIOMS Committee on Vaccine Safety to work with leading regulators from the US, Europe, Canada, Japan and other countries to set standards for global vaccine safety.

    In recognition of her excellent performance, the final meeting for that committee was hosted by the FDA in Accra in 2016, first time ever in sub-Saharan Africa.

    Due to her growing status and being frequently requested by the international agencies to not only attend, but to be a speaker at their meetings, the vaccines unit of the FDA was added to her department in 2012/2013 by Dr Opuni, just prior to his departure from the FDA.

    Her expertise has led to the FDA being nominated and recognised by the NEPAD/African Medicines Regulation Harmonisation (AMRH), Regional Centres of Regulatory Excellence in three very critical areas, namely medicines safety (pharmacovigilance), clinical trials and drug registration.

    She single-handedly led a collaboration of the FDA with the UK-MHRA in the area of medicine safety; this collaboration is now multi-divisional at the FDA with anti-counterfeiting as one of the key areas of support.

    She is a founding member of AVAREF, the African Vaccines Regulatory Forum, and was nominated last year to serve on the Technical Coordinating Committee (TCC) of the newly-organised AVAREF. This has put Ghana in the forefront of research regulation in Africa and has ensured tremendous support to the country in the area of clinical trials.

    She has served as an expert advisor on the African Regulators Network (ARN) and worked tirelessly to ensure harmonisation of regulatory systems across Africa.

    Credit: starrfmonline

    Comments...

    ABRAHAM GYESIE says...
    Posted Tuesday, March 07, 2017
    I congratulate Pharm Mimi Darko on her appointment as the new FDA CEO. She is truly an excellent choice.She is hard working and highly professional in her approach and carriage. May God bless all her lawful and laudable endeavours.
    DORSAH GARIBA says...
    Posted Thursday, February 23, 2017
    Congratulations Pharm Darko! I was posted to do my service at the FDB in 1996, after visiting there 2X for info and orientation, I was told to begin the following day. The next day upon arrival to work I was told that 37 Military Hospital Chief Pharmacist has put up a request and demand for me to do my service at 37 Military Hospital. So I was told to go and see the Col there. I resisted but Mr Quaquay spoke very nicely to me and said I can come back after 12 months if I don't like it. To make long story short, I was told I will be working with Pharm Darko at the time.